



Supplementary Figure 3. Trametinib induced p-ERK downregulation in melanoma cell lines independent of their *BRAF/NRAS* and *NF1* status. Treatment with trametinib 5nM for 6h induces downregulated p-ERK in *BRAF/NRAS* wild type *NF1* positive cell lines, and in controls.